Gemina Laboratories Ltd. (CSE:GLAB)

Market Cap	38.29M
Revenue (ttm)	10.88K
Net Income (ttm)	-4.01M
Shares Out	76.57M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	7,650
Open	0.5200
Previous Close	0.5800
Day's Range	0.5000 - 0.5200
52-Week Range	0.2800 - 1.2500
Beta	0.48
RSI	35.58
Earnings Date	Aug 29, 2025

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: GLAB